Natco gets EIR from USFDA for Kothur facility

Company's shares were trading 1.10% higher at Rs 641 on BSE in afternoon session

Drug firm Natco Pharma on Tuesday said it has received Establishment Inspection Report (EIR) for its Kothur facility in Telangana from the US health regulator after successful completion of inspection.

"Natco Pharma is pleased to announce successful EIR from the US Food and Drug Administration (USFDA) for the inspection conducted at its drug manufacturing facility in Kothur Village, Mahaboob Nagar District, during the period February 29 - March 7, 2016," the company said in a BSE filing.

"The Kothur facility predominantly caters to regulated international markets, including USA," it added.

EIR is given to an establishment after the completion of the inspection by the USFDA.
 

Natco Pharma shares were trading 1.10% higher at Rs 641 on BSE in afternoon session.